Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
This suggests Novo may have just a few months to establish a foothold in the oral GLP-1 market before facing competition
DSIP is being studied for its potential to help normalize stress hormone secretion, reduce anxiety-related arousal, and support the nervous systems transition into a restful state without the sedation or dependency risks associated with benzodiazepines or z-drugs
Survodutide is a candidate drug in the obesity treatment pipeline, belonging to a class of dual GLP-1 and GCGR agonists
Previous weight loss medications targeted just one or two of these pathways
The shift toward home delivery models further supports adherence and market expansion
